Most Read Articles
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Roshini Claire Anthony, 07 Nov 2017

Women who are underweight, particularly in their late teens and mid-thirties, may be at risk for early menopause, a recent study found. 

16 Aug 2014

New drug applications approved by US FDA as of 15-30 Aug which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Audrey Abella, 20 Jan 2017
Diabetes was not a risk factor for total knee replacement (TKR) due to severe knee osteoarthritis, a Singapore study found.

Glycaemic control, medication persistence better with canagliflozin vs sitagliptin

10 Oct 2017

Use of canagliflozin in the treatment of type 2 diabetes mellitus (T2DM) leads to greater reductions in glycosylated haemoglobin (HbA1c) and improved medication persistence when compared with sitagliptin, according to a study.

Researchers used data from a US health care administrative database and identified adult T2DM patients who used either canagliflozin (n=3,993) or sitagliptin (n=12,153). They performed propensity score matching to control for baseline differences between the two patient groups, resulting in the inclusion of 1,472 patients per group.

Patients were aged 56 years on average, and more than 50 percent were men. Clinical characteristics were well balanced, with 428 patients in each group having HbA1c ≥7 percent.

Results revealed that the main outcomes of change in HbA1c and persistence with medication over a follow-up of 9 months after index date were better with canagliflozin than with sitagliptin.

Specifically, reductions in HbA1c were −0.93 in the canagliflozin group vs −0.57 percent in the sitagliptin group (p=0.004). The mean time from index date to follow-up HbA1c was similar (185.4 vs 184.3 days, respectively; p=0.802).

Fewer patients on canagliflozin discontinued their medication during follow-up (29.8 vs 41.5 percent in the sitagliptin group; p<0.001). The average days of persistence on index therapy was also longer in the canagliflozin group (152 vs 139 days; p<0.001).

The present data, which demonstrate the superiority of canagliflozin over sitagliptin in the treatment of T2DM, are in line with those reported in previous clinical trials. [Diabetologia 2013;56:2582–2592; Diabetes Care 2013;36:2508–2515; Postgraduate Med 2016;128:725–730]

Nevertheless, identifying the optimal diabetes treatment choice in routine practice necessitates more studies aimed at providing a better understanding of antihyperglycaemic treatment, HbA1c results and differences among patients in demographic/clinical characteristics, as well as persistence with treatment, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
25 Aug 2015
At the Northern Pharmacists Convention cum 48th Malaysian Pharmaceutical Society Seminar 2015 held recently at Bayview Beach Hotel, Penang, Sanofi invited three distinguished speakers – Dr Khaw Chong Hui, Dr Lo Kang Shang Chit, and Professor Dr Karl-Josef Gundermann – to speak on the importance of renal protection in managing diabetic hypertension, the use of antihistamines in managing chronic urticaria (CU), and the role of essential phospholipids (EPL) in fatty liver diseases, respectively.
Roshini Claire Anthony, 07 Nov 2017

Women who are underweight, particularly in their late teens and mid-thirties, may be at risk for early menopause, a recent study found. 

16 Aug 2014

New drug applications approved by US FDA as of 15-30 Aug which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Audrey Abella, 20 Jan 2017
Diabetes was not a risk factor for total knee replacement (TKR) due to severe knee osteoarthritis, a Singapore study found.